Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Author(s):
Weinblatt, M.E.; Genovese, M.C.; Ho, M.; Hollis, S.; Rosiak-Jedrychowicz, K.; Kavanaugh, A.; Millson, D.S.; Leon, G.; Wang, M.; Heijde, D. van der
Published
2014
Publication type
Article / Letter to editor
Date issued
2014-12-31
Language
English
Is part of
Arthritis and Rheumatology (2014), Vol. 66, no. 12, p. 3255-3264
